Hologic Diagenode’s Post

Introducing the Cutting-Edge in Methylation Analysis: Infinium Methylation Screening Array (MSA) We're thrilled to announce the launch of a groundbreaking product in the field of genetic research, Illumina’s Infinium Methylation Screening Array (MSA). This pioneering array marks the debut of our new EX platform, a leap forward in array format, assay chemistry, and automation systems. Key Features of MSA: 1. Expert Design: Over 270K carefully curated probes, offering insights into validated human disease associations, emerging methylation biomarkers, and functional epigenomics. 2. Multiomic Capabilities: Unleashing the power of integrated genomic analysis. 3. Enhanced Efficiency and Scalability: The 48-EX format enables processing up to 600K samples/year on a single iScan. 4. Lower DNA Input Requirements: Just 50 ng, streamlining sample preparation. For further details: https://lnkd.in/dmWyKQAD

𝐁𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲: 𝐑𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐢𝐧𝐠 𝐭𝐡𝐞 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 𝐑𝐞𝐚𝐝 𝐌𝐨𝐫𝐞: https://lnkd.in/d-JzwCXY This article delves into the importance of 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲, its methodologies, challenges, and its profound impact on the proteomics industry. #biomarkerdiscovery #proteomics #personalizedmedicine #biomedicalresearch #healthinnovation

In a new blog post at Enseqlopedia I talk about an exciting preprint from Tagomics, which describes their novel epigenomic profiling approach called “Active-Seq”, a bisulfite-free method designed to enrich unmethylated DNA as opposed to enriching methylated (e.g. MeDIP, GH) or everything (e.g. Twist, Grail). Think MeDIP but for non-methylated CpGs. https://lnkd.in/eyj2ztA3

There's still time to join Olink Insight's technical webinar! If you're in proteomics, this is something you won't want to miss. Olink Insight streamlines study size calculations, matches panels to your wish markers, and converts gene lists to protein lists in minutes. Check it out at https://lnkd.in/dqD6EBum.

🚀 We’re excited to announce the launch of PGXI, a new knowledgebase designed to advance insights into pharmacogenomics, the study of how an individual’s genetic makeup influences their response to medications. Learn more 👉 https://lnkd.in/eJbTmHRf ✅ This new knowledgebase offers expert-curated content on how genetic variations influence drug response. ✅ PGXI centralizes data and automates annotation, enabling researchers to rapidly generate genomic and drug insights. ✅ It enhances the understanding of pharmacogenomics, helping to reduce treatment-related side effects and optimize drug development and delivery.

Check out this excellent summary of our recent preprint by James Hadfield in his latest Enseqlopedia blog post! - https://lnkd.in/eyj2ztA3 You can access our preprint paper here: https://lnkd.in/eQpyYvUE

Looking forward to #SLAS2024 where we will be showcasing our ioCRISPR-Ready Cells™️ products. Our poster presentations will include data from two products - the recently launched CRISPR-Ready ioGlutamatergic Neurons™️ and the next product in the range - CRISPR-Ready ioMicroglia™️. Find out more in the press release. 👇📰 https://hubs.ly/Q02j60Vz0 ioCRISPR-Ready Cells are iPSC-derived human cells containing a constitutively-expressed Cas9 nuclease. They arrive ready-to-use and with simple protocols, allowing high gene knockout efficiencies and functional experimental readouts in a physiological relevant cellular model in days, significantly reducing experimental timelines. #CRISPR #Research #DrugDevelopment #SynBio #BioEngineering

The core achievement of Chai-1 is its ability to predict complex molecular interactions involving proteins, small molecules, DNA, RNA, and even covalent modifications. This comprehensive scope makes it one of the most versatile tools for molecular structure prediction today. @marktechpost

How can genetic testing help to include more diverse participants in clinical trials and studies for drug discovery and biopharma? Sir Peter Donnelly CEO and Co-Founder of Genomics plc, answers this question and many more about our Polygenic Risk Scoring during this roundtable about how Genomics can enable individuals to live longer, healthier lives: https://lnkd.in/eQEhW-wf

Long non-coding RNAs will be the next gold mine for novel drug targets. In the past two weeks, we saw two major partnerships announced, specifically hunting for lncRNA targets: HAYA Therapeutics and Eli Lilly and Company - $1B+ NextRNA Therapeutics and Bayer - $550M+ The hardest part is deciding which lncRNA to target. LncRNAs have cell-type, tissue-type, and disease specific expression patterns. They're involved in complex and often pleiotropic biological processes. Epigenetics is notoriously hard. You have to integrate bioinformatic data from all kinds of experiments (ChIP, ChIRP, RIP, eCLIP, ATAC, etc...) to understand the epigenetic landscape and test your hypotheses. "What does my lncRNA bind with?" and "Where does the lncRNA-protein complex bind to on the genome?" and "Are they promoters? Enhancers? Is the region even accessible in my cell type? Tissue? Disease?" and "Do those genes show expression changes when I knock down my lncRNA?" These types of multi-hop questions are where knowledge graphs shine. Traversing these paths and finding patterns become trivial once you've modeled and loaded the data into a knowledge graph on the BioBox platform. Interested in learning more? DM me and let's chat. #ncRNA #KnowledgeGraph #epigenetics